Premium
The pharmacokinetics and safety profile of oral ganciclovir in combination with trimethoprim in HIV‐ and CMV‐seropositive patients
Author(s) -
Jung Donald,
AbdelHameed Magdy H.,
Hunter John,
Teitelbaum Philip,
Dorr Albert,
Griffy Kay
Publication year - 1999
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.1999.00876.x
Subject(s) - ganciclovir , pharmacokinetics , trimethoprim , medicine , pharmacology , crossover study , adverse effect , cmin , oral administration , antibiotics , cmax , human cytomegalovirus , virology , placebo , biology , virus , microbiology and biotechnology , alternative medicine , pathology
Aims We investigated the pharmacokinetics and safety profile of oral ganciclovir coadministered with trimethoprim in HIV‐and CMV‐seropositive patients.Methods In an open‐label, randomized, 3‐way crossover study, 12 adult males received oral ganciclovir 1000 mg every 8h, oral trimethoprim 200 mg once daily, or both drugs concomitantly in a sequence of three 7‐day treatment periods. Pharmacokinetic parameters were determined and adverse events recorded for each treatment.Results The presence of trimethoprim significantly decreased CL r (12.9%, P=0.0068) and increased t 1/2 (18.1%, P=0.0378) of ganciclovir. However, these changes are unlikely to be clinically meaningful. There were no statistically significant changes in trimethoprim pharmacokinetic parameters in the presence of ganciclovir, with the exception of a 12.7% increase in C min . Ganciclovir was well tolerated when administered alone or in combination with trimethoprim.Conclusions There was no clinically significant pharmacokinetic interaction between oral ganciclovir and trimethoprim when coadministered.